Centessa Pharmaceuticals Statistics
Total Valuation
CNTA has a market cap or net worth of $6.12 billion. The enterprise value is $5.97 billion.
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CNTA has 154.66 million shares outstanding. The number of shares has increased by 14.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 154.66M |
| Shares Change (YoY) | +14.73% |
| Shares Change (QoQ) | +8.15% |
| Owned by Insiders (%) | 0.64% |
| Owned by Institutions (%) | 58.75% |
| Float | 97.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 12.57 |
| P/TBV Ratio | 12.57 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.53, with a Debt / Equity ratio of 0.24.
| Current Ratio | 9.53 |
| Quick Ratio | 9.11 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.69 |
Financial Efficiency
Return on equity (ROE) is -57.38% and return on invested capital (ROIC) is -28.92%.
| Return on Equity (ROE) | -57.38% |
| Return on Assets (ROA) | -27.43% |
| Return on Invested Capital (ROIC) | -28.92% |
| Return on Capital Employed (ROCE) | -42.41% |
| Weighted Average Cost of Capital (WACC) | 10.47% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.12M |
| Employee Count | 118 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CNTA has paid $1.27 million in taxes.
| Income Tax | 1.27M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +191.82% in the last 52 weeks. The beta is 1.14, so CNTA's price volatility has been higher than the market average.
| Beta (5Y) | 1.14 |
| 52-Week Price Change | +191.82% |
| 50-Day Moving Average | 33.72 |
| 200-Day Moving Average | 25.52 |
| Relative Strength Index (RSI) | 72.65 |
| Average Volume (20 Days) | 2,174,343 |
Short Selling Information
The latest short interest is 3.47 million, so 2.58% of the outstanding shares have been sold short.
| Short Interest | 3.47M |
| Short Previous Month | 6.61M |
| Short % of Shares Out | 2.58% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.73 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -256.69M |
| Pretax Income | -249.37M |
| Net Income | -250.64M |
| EBITDA | -256.35M |
| EBIT | -256.69M |
| Earnings Per Share (EPS) | -$1.78 |
Full Income StatementBalance Sheet
The company has $276.59 million in cash and $117.81 million in debt, with a net cash position of $158.78 million or $1.03 per share.
| Cash & Cash Equivalents | 276.59M |
| Total Debt | 117.81M |
| Net Cash | 158.78M |
| Net Cash Per Share | $1.03 |
| Equity (Book Value) | 487.35M |
| Book Value Per Share | 3.15 |
| Working Capital | 312.11M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$208.80 million and capital expenditures -$371,000, giving a free cash flow of -$209.17 million.
| Operating Cash Flow | -208.80M |
| Capital Expenditures | -371,000 |
| Depreciation & Amortization | 343,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -209.17M |
| FCF Per Share | -$1.35 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.73% |
| Shareholder Yield | -14.73% |
| Earnings Yield | -4.09% |
| FCF Yield | -3.42% |
Analyst Forecast
The average price target for CNTA is $43.17, which is 9.02% higher than the current price. The consensus rating is "Buy".
| Price Target | $43.17 |
| Price Target Difference | 9.02% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 87.10% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
